ALK awaits crucial adrenaline data in 2021 and plans to submit FDA application in less than three years

Allergy company ALK will receive crucial trial data from partner Windgap which is working on a next-generation adrenaline pen which ALK has the rights to. Meanwhile, ALK is developing its own adrenaline pen based on experiences with Jext. The firm is confident it will be submitting a registration application to the US FDA before 2024.

Photo: Gregers Tycho/Ritzau/Ritzau Scanpix

ALK's allergy specialists want more than a dominant position in the US market for tablet treatments for patients with allergies.

The company aspires to become world-leading in the US for selling epinephrine pens, which used for the treatment of anaphylaxis caused by allergies to certain foods or bee stings, for example.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs